For example, there is evidence to suggest that the use of dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of medications commonly prescribed for the management of diabetes, may be associated with an increased risk of BP. This evidence concerns the gene DPP4 and diabetes mellitus.